deltatrials
Completed PHASE2 NCT03990363

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients With Chronic KIdney Disease and Hyperuricaemia

Sponsor: AstraZeneca

Conditions Chronic Kidney Disease
Interventions Allopurinol Placebo for Allopurinol Placebo for Verinurad Verinurad
Updated 20 times since 2019 Last updated: Feb 1, 2023 Started: Jul 23, 2019 Primary completion: Nov 22, 2021 Completion: Nov 22, 2021

This PHASE2 trial investigates Chronic Kidney Disease and is currently completed. AstraZeneca leads this study, which shows 20 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

20 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Feb 2022 — Apr 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  6. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  8. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE2

  10. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  11. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  12. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  13. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  14. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Jul 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel, Alexandria, United States, Alicante, Spain, Altamonte Springs, United States, Annonay, France, Arlington, United States, Ashdod, Israel, Asheville, United States, Ashkelon, Israel, Baja, Hungary and 128 more location s